ipsbio

iPS Bio is a South Korean biotechnology company established in 2019 that focuses on providing innovative solutions for intractable neurological diseases using induced pluripotent stem cell (iPSC) technology. The company develops therapeutics, including iPSC-derived neural precursor cell therapies for conditions such as Huntington’s disease, stroke, and Alzheimer’s disease, as well as small molecule drug candidates. Its research integrates patient-derived iPSCs and AI technology to create advanced drug discovery and screening platforms. Furthermore, the company offers personalized services, such as its My iCell Bank for customized iPSC generation and banking, aimed at advancing precision regenerative medicine.

By leveraging these stem cell-based approaches, iPS Bio aims to address unmet medical needs by restoring lost neurons and providing neuroprotective effects. The company’s pipeline includes various programs in preclinical stages, with research supported by partnerships and various grants within the regenerative medicine sector. Through its commitment to patient-centered treatment innovation, iPS Bio seeks to improve quality of life and deliver novel therapeutic options for neurodegenerative disorders, supported by a leadership team with extensive experience in stem cell research and global scientific collaboration.